Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the PK properties of lorcaserin in subjects with end stage renal disease (ESRD) who require dialysis and will be studied under dialysis and non-dialysis conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05940402

Renal Impairment

COMPLETED PHASE1

A Multi-Center, Open-Label Study

NCT01468259

Renal Disease End Stage Renal Disease

WITHDRAWN PHASE1

A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)

NCT06814119

Healthy Renal Impairment

RECRUITING PHASE1

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

NCT05099445

Renal Impairment Hemodialysis

COMPLETED PHASE1

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

NCT02399202

Renal Impairment

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lorcaserin 10mg

Group Type EXPERIMENTAL

Lorcaserin 10mg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lorcaserin 10mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females aged between 18 and 79 years (inclusive)
2. Able to give signed informed consent
3. Renal function will fall into one of the following categories (ideal body weight will be used for the calculation):

* One-fifth of subjects will have normal renal function, defined as creatinine clearance \> 80 mL/min calculated using the Cockroft-Gault equation
* One-fifth of subjects will have creatinine clearance 51-80 mL/min
* One-fifth of subjects will have creatinine clearance 31-50 mL/min
* One-fifth of subjects will have creatinine clearance 5-30 mL/min, but not require dialysis
* One-fifth of subjects will have chronic end stage renal disease, require regularly scheduled hemodialysis, and be on a stable hemodialysis regimen for at least 3 months prior to dosing
4. Subjects in the renally impaired groups will have stable renal disease as per Investigator's assessment, with no clinically meaningful changes for 1 month prior to randomization.
5. Subjects in all groups will have a BMI of 27-45 kg/m2.
6. Considered to be in stable health in the opinion of the Investigator.
7. Eligible male and female subjects must agree not to participate in a conception process.

Exclusion Criteria

1. Prior participation in any study of lorcaserin.
2. Clinically significant new illness in the 1 month before screening
3. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
4. History of any of the following cardiovascular conditions:

* Myocardial infarction (diagnosed by cardiac enzyme\[s\] and/or diagnostic ECG), CVA, TIA or RIND within 3 months of screening
* Cardiac arrhythmia requiring initiation of a new medical or surgical treatment within 3 months of screening (pacemaker and/or defibrillator implanted \> 3 months prior to screening is acceptable)
* Unstable angina
* History of pulmonary artery hypertension
5. Positive result of HIV, hepatitis B or hepatitis C screens.
6. Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
7. Use of SSRI's, SNRI's, and other medications must meet washout period.
8. Recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
9. Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing
10. Unwilling, or whose partner is unwilling, to use an adequate means of contraception during and for 1 month following completion/withdrawal of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes